Brief: Epigenomics Is Evaluating M&A Options
25/03/2021 09:51
March 25 (Reuters) - Epigenomics AG ECXn.DE :
* IS EVALUATING M&A OPTIONS
* FOR THIS PURPOSE, A CORRESPONDING SALES PROCESS HAS BEEN
SET UP
AND COMPANY IS IN DISCUSSIONS WITH SEVERAL POTENTIAL PARTIES
* IS EVALUATING MARKET FOR A POTENTIAL SALE OF COMPANY BY
WAY OF A
SHARE DEAL (PUBLIC TAKEOVER) OR ASSET DEAL TO ONE OR MORE
INVESTORS AS PART OF AN M&A TRANSACTION
Source text for Eikon: ID:nEQ4qFkhxa
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns